RNA-drug developer Quark aims for $30M after failed IPO
See our story on this Fremont, Calif., developer of RNA-interference drugs at VentureBeat Life Sciences.
Next Story: Opposing Views, a discussion Web site, raises $1.5M
Previous Story: A new wave of better Facebook applications. Example: Frengo
About the Author, David P. Hamilton
David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.